Grey
Brand Name(s):Tarceva
Indication:Non-small-cell lung cancer (Maintainance)
Rationale:1
Considered:Jan-07
Review Date:Feb-26
Comments:
NICE TA374 replaces TA258
Drug Safety Update/Roche Feb 2016
NICE TA258 June 2012
NICE TA227 June 2011
Risks of incorrect dosing of oral anti-cancer medicines – NPSA January 2008